"On 18 July, Race CEO, Dr Daniel Tillett, was selected to present “Discovery of bisantrene as a dual cardioprotective and anticancer agent in combination with doxorubicin” at the European Society of Medical Oncology (ESMO) 2025 conference to be held in Berlin on the 17-21 October 2025 by the ESMO 2025 Scientific Committee."
This represents the first time that the mechanism of action of bisantrene will be shared with the world, at one of the largest oncology congresses in the world. Many are also expecting a significant update to the strategy to be released before or around this time also, along with data from numerous other preclinical activities rumoured to have been commenced.
RAC Price at posting:
$1.18 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)